Presentation

Vaccines remain one of the most effective ways to combat infectious diseases. Improving our knowledge in vaccinology and developing new vaccine technologies, undoubtedly improves public acceptance confidence in vaccination. Since its establishment, the network has brought together clinicians and academic researchers to expand our knowledge in vaccinology, encourage the development of new vaccine technologies, and facilitate multidisciplinary and collaborative clinical research projects.

The I-REIVAC network's mission and ambition is to promote clinical research in vaccinology and monoclonal antibodies, both nationally and internationally, by:

• Improving France's attractiveness to conduct industrial trials, particularly for early phase studies (I and II);
• Boosting clinical research, particularly regarding the vaccination of specific populations (patients with comorbidities, immunocompromised patients, elderly populations, etc.)
• Contributing to preparedness and response to future pandemics;
• Fostering the emergence of translational (or exploratory) research through interactions between clinicians, biologists, academic researchers, and the industry;
• Formalising public-private partnerships, including with research teams, clinical research networks (particularly other F-CRIN-certified networks), and industrial and institutional stakeholders;
• Opening the network's activities to new stakeholders, such as general practice, and in strategic fields related to innovative therapies;
• Stimulating new collaborations at a European and international level.

The expertise of the I-REIVAC network is divided into 5 areas:

1. The implementation of clinical trials on new vaccines and monoclonal antibodies focussed on the prevention of infectious diseases;
2. The vaccination of special populations by promoting the development of international collaborations, particularly in patients with rare and/or complex diseases (immunocompromised, diabetics, patients with autoimmune diseases, solid organ or hematopoietic stem cell transplant recipients, pregnant women, the elderly) while assessing of the benefit/risk ratio of vaccination in these populations ;
3. The evaluation of immunological mechanisms and  vaccine response determinants, including the identification of biomarkers and correlates of protection;
4. Epidemiological and burden studies of vaccine-preventable diseases ;
5. The development of a Human and Social Sciences (SHS) axis to understand the determinants of vaccine acceptability or refusal ;

In 2025, I-REIVAC is composed of:

• A network of more than thirty clinical centers (Clinical Investigation/Research Centers (CIC/CRC) and/or Infectious and Tropical Diseases Services (ITDS)).
• A network of biological resource centers (BRCs) including 3 coordinating centers.
• A network of around 10 immuno-monitoring laboratories,
• Three associated methodology and management centers (CMGs).

1. A structured network made up of various players experienced in vaccine clinical research ;
2. A coordinating team dedicated and responsive to implement studies ;
3. An ambitious scientific program;
4. Clinical studies conducted in accordance with good clinical practice, current regulations, ethics and Quality Assurances ;
5. Continuous training in vaccinology and clinical research.